Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis

Please use this link to access this publication. Abstract Cannabidiol (CBD) is a non-psychoactive substance that exerts numerous pharmacological benefits, including anti-inflammatory and antioxidant properties.

February 21, 2026

Quantitative natural language processing markers of psychoactive drug effects: A pre-registered systematic review

Abstract Psychoactive substances used for recreational purposes have mind-altering effects, but systematic evaluation of these effects is largely limited to self-reports. Automated analysis of expressed

May 17, 2026

Quantitative determination and validation of 96 pesticides in cannabis by LC-MS/MS and GC-MS/MS

Abstract Canada has established a strict set of testing requirements for pesticides that are unauthorized for use on cannabis, currently holding the most extensive list

February 15, 2026

Quantitative Analysis of Propofol Dosage in Cannabis Users: A Systematic Review and Meta-Analysis

Background: Rising cannabis use poses significant challenges in the administration of general anesthetics, particularly propofol, due to potential alterations in pharmacodynamics caused by tetrahydrocannabinol and

January 11, 2026

Quantification of Cannabis in Infused Consumer Products and Their Residues on Skin

Please use this link to access this publication. Abstract Cannabis consumer products are a $4.6 billion industry in the U.S. that is projected to exceed $14

December 17, 2024

Quantification and time course of subjective psychotropic and somatic effects of tetrahydrocannabinol – a prospective, single-blind, placebo-controlled exploratory trial in healthy volunteers

Abstract Background Cannabis is increasingly used and debates about the legalisation of the recreational use of cannabis are ongoing. In this prospective, placebo-controlled study in

May 2, 2026

Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy

Please follow this link to access this publication: https://www.sciencedirect.com/science/article/abs/pii/S1525505019301167 Abstract Treatment-resistant epilepsy (TRE) is associated with low quality of life (QOL). Cannabidiol (CBD) may improve

November 15, 2023

Quality of life and cannabis use among patients with drug-resistant epilepsy—An observational study from a Canadian tertiary care referral center

Abstract Objective Very few publications have reported the impact of artisanal cannabis use on overall quality of life among people with drug-resistant epilepsy. This study

February 1, 2026

Qualifying Conditions Of Medical Cannabis License Holders In The United States

Abstract The evidence for cannabis’s treatment efficacy across different conditions varies widely, and comprehensive data on the conditions for which people use cannabis are lacking.

August 1, 2024

Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report

Please use this link to access this publication. Abstract Objectives Anecdotal reports and preliminary studies suggest a therapeutic potential of cannabis in Tourette syndrome. We